LimmaTech Biologics AG has pioneered vaccine development technologies to develop next generation vaccines to prevent severe diseases caused by microbial pathogens. Leveraging its decades of understanding microbial pathogens, expertise in innovative vaccine technologies and clinical development, LimmaTech is advancing its own proprietary pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance and sexually transmitted infections such as S. aureus, Gonorrhoeae and Chlamydia, alongside partnered programs with GSK and Valneva. LimmaTech is committed to translating novel scientific concepts into highly effective vaccines that benefit humanity.